Skip to main page content
U.S. flag
See More

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Mar 16;107(11):4813-9.
doi: 10.1073/pnas.0909422107. Epub 2010 Mar 1.

Leptin therapy in insulin-deficient type I diabetes

May-yun Wang  1 , Lijun Chen, Gregory O Clark, Young Lee, Robert D Stevens, Olga R Ilkayeva, Brett R Wenner, James R Bain, Maureen J Charron, Christopher B Newgard, Roger H Unger
Affiliations

Leptin therapy in insulin-deficient type I diabetes

May-yun Wang et al. Proc Natl Acad Sci U S A. .

Abstract

In nonobese diabetic mice with uncontrolled type 1 diabetes, leptin therapy alone or combined with low-dose insulin reverses the catabolic state through suppression of hyperglucagonemia. Additionally, it mimics the anabolic actions of insulin monotherapy and normalizes hemoglobin A1c with far less glucose variability. We show that leptin therapy, like insulin, normalizes the levels of a wide array of hepatic intermediary metabolites in multiple chemical classes, including acylcarnitines, organic acids (tricarboxylic acid cycle intermediates), amino acids, and acyl CoAs. In contrast to insulin monotherapy, however, leptin lowers both lipogenic and cholesterologenic transcription factors and enzymes and reduces plasma and tissue lipids. The results imply that leptin administration may have multiple short- and long-term advantages over insulin monotherapy for type 1 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1.
Fig. 1.
Comparisons of various parameters in plasma of type 1 diabetic NOD mice. Mice were either untreated or treated with s.c.-infused leptin (•; n = 14) through an Alzet pump or with insulin delivered from a s.c. pellet (▲; n = 6). Untreated mice were either fed ad libitum (○; n = 4) or pair-fed with the leptin-treated group (△; n = 4), and all received an infusion of PBS through an Alzet pump. (A) Plasma leptin levels. (B) Blood glucose levels. (C) Plasma FFA levels. (D) Hemoglobin A1c (day 0 =■ day 12 = □). The dotted lines mark the normal values.
Fig. 2.
Fig. 2.
TG concentrations in plasma and liver and expression levels of transcription factors and enzymes involved in lipogenesis and cholesterologenesis in livers of type 1 diabetic NOD mice treated either with s.c.-infused leptin (formula image) or insulin delivered from an s.c. pellet (■). Untreated controls infused with PBS were either fed ad libitum (□) or pair-fed (PF) to the leptin-treated group (formula image). (A) Plasma TG concentration. (B) Liver TG content. (C) Hepatic expression of a lipogenic transcription factor, LXRα and SREBP-1c, and lipogenic enzymes, FAS and GPAT. (D) Hepatic expression of transcription factors, SREBP-1a and -2, and enzyme, HMG CoA reductase, involved in cholesterologenesis. Relative expression signifies the ratio of the mRNA of interest to the mRNA of 36B4, the invariant control. The broken horizontal lines indicate the relative expression level of the mRNA in nondiabetic control mice. [*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001 vs. ad libitum–fed untreated (PBF) controls; †P ≤ 0.05; ††P ≤ 0.01; †††P ≤ 0.001 leptin treatment vs. insulin.]
Fig. 3.
Fig. 3.
Plasma glucagon levels and activation of its transcription factor, CREB, and a target enzyme in livers of type 1 diabetic NOD mice treated with s.c.-infused leptin (formula image) or PEPCK insulin delivered from an s.c. pellet (■); untreated controls were infused with PBS and fed ad libitum (□) or PF to the leptin-treated group (formula image). (A) Ratio of phosphorylated to total AMPK. (B) Plasma glucagon. (C) Ratio of phosphorylated to total CREB. (D) mRNA of phosphoenol pyruvate carboxykinase. (E) Ratio of phosphorylated to total STAT-3. ND, nondiabetic. (*P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001 vs. ad libitum fed untreated PBF controls.)
Fig. 4.
Fig. 4.
(A) Comparison of blood glucose levels in glucagon receptor null (Gcgr−/−) mice (□) and wild-type (Gcgr+/+) controls (•) after treatment with double-dose alloxan. (B) Comparison of severity of insulin deficiency in the alloxan-treated Gcgr−/− and Gcgr+/+ and nondiabetic Gcgr−/− and Gcgr+/+ controls based on plasma insulin levels and morphometric values for insulin-immunostained β-cells in pancreata. The results indicate no significant difference in residual insulin that could explain the absence of hyperglycemia in the alloxan-treated Gcgr−/− group. Nondiabetic, □; alloxan diabetic, ■.
Fig. 5.
Fig. 5.
Examples of metabolomic patterns of four classes of metabolites in livers of nondiabetic (formula image), untreated diabetic (□), diabetic treated with insulin pellets (■), and diabetic leptin-treated mice (formula image). (A) Acyl carnitines reflecting branch-chain amino acid metabolism and ketone production. (B) Long-chain acyl Co As and acyl carnitines (Inset). (C) Branch-chain amino acids. (D) Organic acids. Of 121 metabolites measured, 67 were abnormal in untreated diabetes. Of these, 55 were corrected or improved by both hormones. Three were corrected by leptin but not insulin. Three were corrected by insulin but not leptin. The remainder were not corrected.
Fig. 6.
Fig. 6.
(A) Comparison of plasma glucose levels in type 1 diabetic NOD mice treated with twice daily injection of insulin alone at a total dose of 0.2 U/day (▲), twice daily insulin alone at a total dose of 0.02 U/day fed ad libitum (○), twice daily insulin PF to the leptin-treated group (□), or a total daily dose of insulin of 0.02 U/day plus leptin injected at the doses and times indicated by arrows (•). (B) Evidence that much lower doses of infused leptin without insulin are also effective in reducing the hyperglycemia of T1DM. Blood glucose levels of diabetic NOD mice treated for 20 days with leptin monotherapy by osmotic infusion pump are shown. Priming doses during the first 7 days ranged from 1/500 to 1/2,000 of the doses injected with low-dose insulin, and maintenance doses of infused leptin thereafter ranged from 1/500 to 1/2,500 of the doses of injected leptin employed.
See this image and copyright information in PMC

Comment in

  • Leveraging leptin for type I diabetes?
    Kraus D, Herman MA, Kahn BB. Kraus D, et al. Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):4793-4. doi: 10.1073/pnas.1000736107. Epub 2010 Mar 8. Proc Natl Acad Sci U S A. 2010. PMID: 20212134 Free PMC article. No abstract available.

References

    1. Banting FG, Best CH. Pancreatic extracts. 1922. J Lab Clin Med. 1990;115:254–272. - PubMed
    1. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: Defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest. 2002;32(Suppl 3):14–23. - PubMed
    1. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;1:785–789. - PubMed
    1. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest. 2000;106:171–176. - PMC - PubMed
    1. Zhou YT, et al. Lipotoxic heart disease in obese rats: Implications for human obesity. Proc Natl Acad Sci USA. 2000;97:1784–1789. - PMC - PubMed

Publication types

MeSH terms